Compare SkyWest Inc (SKYW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs State Street SPDR S&P Biotech ETF — how do they compare? SkyWest Inc trades at $95.26 (market cap $3.94B), while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| SKYW | XBI | |
|---|---|---|
Market Cap | $3.94B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $123.72 | $164.28 |
52-Week Low | $78.40 | $85.16 |
Enterprise Value | $5.79B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $99.34, up 2.17% today, with a neutral technical signal but bullish moving averages. The stock shows strong profitability with a 10.42% net margin and attractive valuation at a P/E of 9.32. Recent earnings have been mixed, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Analyst consensus is bullish with a $109.33 price target, though news highlights concerns over rising fuel costs impacting airline profits.
The outlook for SKYW is cautiously optimistic, supported by solid fundamentals and analyst buy ratings, but faces headwinds from volatile fuel expenses and competitive pressures. Upside potential exists if the company maintains earnings momentum and manages cost inflation, while downside risks include economic sensitivity and operational challenges in the airline industry.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
